The drugmaker aimed to move the lawsuits to federal court so it could forge a single defense strategy.
U.S. District Judge Maryellen Noreika dismissed J&J’s request, arguing that the drugmaker is partially responsible for the “bloomlet of litigation,” according to the report.
“J&J’s desire to centralize its own state law litigation does not justify the finding of an emergency” requiring immediate transfer, she added in her 11-page ruling.
J&J is facing 14,000 claims that its talc products contained traces of asbestos, which caused people’s ovarian cancer or mesothelioma.
More articles on pharmacy:
Insys execs guilty of opioid racketeering scheme
Walgreens shaking up C-suite
Generic drugmakers could thrive in a recession, Moody’s says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
